Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808404 | 0.85 | NPC1 (0.51) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL8306572 | 0.85 | NPC1 (0.51) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL7804889 | 0.83 | NPC1 (0.50) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL7806938 | 0.83 | NPC1 (0.50) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL11923450 | 0.82 | NPC1 (0.49) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL12516865 | 0.82 | L3MBTL3 (0.53) | L3MBTL1NPC1L3MBTL3 | |
| SCHEMBL11196 | 0.81 | NPC1 (0.47) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL7458529 | 0.81 | L3MBTL3 (0.49) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL13673411 | 0.81 | L3MBTL3 (0.49) | GNAI3GNAI1GNAO1L3MBTL1NPC1 | |
| SCHEMBL7485454 | 0.80 | GNAI3 (0.60) | GNAI3GNAI1GNAO1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1077891-C | 5-phenyl-3- (piperidin-4-yl) -1,3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT4 or H3 receptor ligands | SYNTHELABO (FR) | 2002-01-16 | — | — | CN | claimed |
| CN-1260794-A | 5-aryl-3-(8-azabicyclo (3.2.2) oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as -5HT4 receptor ligands | SANOFI SYNTHELABO (FR) | 2000-07-19 | — | — | CN | claimed |
| CN-1202169-A | 5-phenyl-3- (piperidin-4-yl) -1, 3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT 4 or H3 receptor ligands | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | claimed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| CN-1260794-A | 5-aryl-3-(8-azabicyclo (3.2.2) oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as -5HT4 receptor ligands | SANOFI SYNTHELABO (FR) | 2000-07-19 | — | — | CN | disclosed |
| CN-1202169-A | 5-phenyl-3- (piperidin-4-yl) -1, 3, 4-oxadiazol-2 (3H) -one derivatives useful as 5-HT 4 or H3 receptor ligands | SYNTHELABO (FR) | 1998-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | GNAI3 2090/4885GNAI1 1467/4885GNAO1 2331/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | GNAI3 2090/4885GNAI1 1467/4885GNAO1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.